Anna Guidetti

2.6k total citations
62 papers, 796 citations indexed

About

Anna Guidetti is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Anna Guidetti has authored 62 papers receiving a total of 796 indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Pathology and Forensic Medicine, 28 papers in Oncology and 15 papers in Genetics. Recurrent topics in Anna Guidetti's work include Lymphoma Diagnosis and Treatment (30 papers), Chronic Lymphocytic Leukemia Research (14 papers) and CAR-T cell therapy research (12 papers). Anna Guidetti is often cited by papers focused on Lymphoma Diagnosis and Treatment (30 papers), Chronic Lymphocytic Leukemia Research (14 papers) and CAR-T cell therapy research (12 papers). Anna Guidetti collaborates with scholars based in Italy, United States and Spain. Anna Guidetti's co-authors include Carmelo Carlo‐Stella, Alessandro M. Gianni, Massimo Di Nicola, Paolo Corradini, Michele Magni, Paola Matteucci, Liliana Devizzi, Loredana Cleris, Silvia L. Locatelli and Lucia Farina and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Anna Guidetti

56 papers receiving 787 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Anna Guidetti Italy	18	355	297	204	182	129	62	796
Robby E. Kibbelaar Netherlands	15	390 1.1×	341 1.1×	195 1.0×	177 1.0×	121 0.9×	49	947
Jun Takizawa Japan	18	428 1.2×	426 1.4×	191 0.9×	340 1.9×	207 1.6×	75	1.1k
Matthew Mei United States	20	523 1.5×	391 1.3×	216 1.1×	121 0.7×	286 2.2×	108	1.1k
Keitaro Tsushita Japan	12	412 1.2×	429 1.4×	219 1.1×	124 0.7×	135 1.0×	25	818
Stanley Frankel United States	13	424 1.2×	362 1.2×	514 2.5×	196 1.1×	211 1.6×	24	1.2k
Anne Ortved Gang Denmark	15	447 1.3×	428 1.4×	234 1.1×	346 1.9×	178 1.4×	59	969
Christian Kneitz Germany	17	206 0.6×	216 0.7×	184 0.9×	585 3.2×	101 0.8×	29	1.1k
Connie Lee Batlevi United States	17	763 2.1×	450 1.5×	270 1.3×	198 1.1×	87 0.7×	83	1.1k
Mark Bishton United Kingdom	20	507 1.4×	477 1.6×	686 3.4×	159 0.9×	209 1.6×	71	1.3k
Ayse U. Akarca United Kingdom	14	475 1.3×	196 0.7×	183 0.9×	253 1.4×	38 0.3×	34	773

Countries citing papers authored by Anna Guidetti

Since Specialization

Citations

This map shows the geographic impact of Anna Guidetti's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna Guidetti with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna Guidetti more than expected).

Fields of papers citing papers by Anna Guidetti

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anna Guidetti. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna Guidetti. The network helps show where Anna Guidetti may publish in the future.

Co-authorship network of co-authors of Anna Guidetti

This figure shows the co-authorship network connecting the top 25 collaborators of Anna Guidetti. A scholar is included among the top collaborators of Anna Guidetti based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anna Guidetti. Anna Guidetti is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Guidetti, Anna, Annamaria De Filippo, Martina Pennisi, et al.. (2023). Nonrestrictive diet does not increase infections during post-HSCT neutropenia: data from a multicenter randomized trial. Blood Advances. 7(19). 5996–6004. 6 indexed citations

Magni, Martina, Silva Ljevar, Annalisa Chiappella, et al.. (2022). Phenotypic Composition of Commercial Anti-CD19 CAR T Cells Affects In Vivo Expansion and Disease Response in Patients with Large B-cell Lymphoma. Clinical Cancer Research. 28(15). 3378–3386. 35 indexed citations

Carniti, Cristiana, Martina Magni, Anna Dodero, et al.. (2021). Tisagenlecleucel and Axicabtagene Ciloleucel Expansion Kinetics and CAR T Cell Attributes in the Infusion Products Are Early Predictors of Clinical Efficacy. Blood. 138(Supplement 1). 3877–3877. 2 indexed citations

Chiappella, Annalisa, Anna Guidetti, Anna Dodero, et al.. (2021). FIRST REPORT OF THE REAL‐LIFE PROSPECTIVE OBSERVATIONAL STUDY “CAR‐T CELL IN DIFFUSE LARGE B‐CELL AND PRIMARY MEDIASTINAL LYMPHOMAS” OF THE ITALIAN SOCIETY OF HEMATOLOGY. Hematological Oncology. 39(S2). 2 indexed citations

Sollini, Martina, Margarita Kirienko, Francesca Ricci, et al.. (2020). Methodological framework for radiomics applications in Hodgkin’s lymphoma. SHILAP Revista de lepidopterología. 4(1). 9–9. 17 indexed citations

Guidetti, Anna, Arabella Mazzocchi, Rosalba Miceli, et al.. (2017). Early reduction of serum TARC levels may predict for success of ABVD as frontline treatment in patients with Hodgkin Lymphoma. Leukemia Research. 62. 91–97. 13 indexed citations

Viviani, Simonetta, Francesco Spina, Arabella Mazzocchi, et al.. (2016). TARC before ASCT Is Highly Predictive of Outcome in Patients with Relapsed or Refractory (R/R) Classical Hodgkin Lymphoma (cHL) after First-Line Therapy. Blood. 128(22). 3009–3009.

Guidetti, Anna, Carmelo Carlo‐Stella, Silvia L. Locatelli, et al.. (2014). Phase II Study of Perifosine and Sorafenib Dual-Targeted Therapy in Patients with Relapsed or Refractory Lymphoproliferative Diseases. Clinical Cancer Research. 20(22). 5641–5651. 27 indexed citations

Farina, Lucia, Francesco Spina, Anna Guidetti, et al.. (2013). Peripheral blood CD34+ cell monitoring after cyclophosphamide and granulocyte-colony-stimulating factor: an algorithm for the pre-emptive use of plerixafor. Leukemia & lymphoma. 55(2). 331–336. 20 indexed citations

10.

Locatelli, Silvia L., Arianna Giacomini, Anna Guidetti, et al.. (2013). Perifosine and sorafenib combination induces mitochondrial cell death and antitumor effects in NOD/SCID mice with Hodgkin lymphoma cell line xenografts. Leukemia. 27(8). 1677–1687. 25 indexed citations

11.

Guidetti, Anna, Carmelo Carlo‐Stella, Silvia L. Locatelli, et al.. (2012). Phase II study of sorafenib in patients with relapsed or refractory lymphoma. British Journal of Haematology. 158(1). 108–119. 38 indexed citations

12.

Guidetti, Anna, Carmelo Carlo‐Stella, Marco Ruella, et al.. (2011). Myeloablative doses of yttrium‐90‐ibritumomab tiuxetan and the risk of secondary myelodysplasia/acute myelogenous leukemia. Cancer. 117(22). 5074–5084. 21 indexed citations

13.

Chiesa, Claudio, Francesca Botta, Angela Coliva, et al.. (2009). Absorbed dose and biologically effective dose in patients with high-risk non-Hodgkin’s lymphoma treated with high-activity myeloablative 90Y-ibritumomab tiuxetan (Zevalin®). European Journal of Nuclear Medicine and Molecular Imaging. 36(11). 1745–1757. 15 indexed citations

14.

Devizzi, Liliana, Anna Guidetti, Corrado Tarella, et al.. (2008). High-Dose Yttrium-90–Ibritumomab Tiuxetan With Tandem Stem-Cell Reinfusion: An Outpatient Preparative Regimen for Autologous Hematopoietic Cell Transplantation. Journal of Clinical Oncology. 26(32). 5175–5182. 46 indexed citations

15.

Chiesa, Claudio, Francesca Botta, Angela Coliva, et al.. (2007). Dosimetry in Myeloablative ⁹⁰ Y-Labeled Ibritumomab Tiuxetan Therapy: Possibility of Increasing Administered Activity on the Base of Biological Effective Dose Evaluation. Preliminary Results. Cancer Biotherapy and Radiopharmaceuticals. 22(1). 113–120. 17 indexed citations

16.

Devizzi, Liliana, Ettore Seregni, Anna Guidetti, et al.. (2006). High-Dose Myeloablative Zevalin Radioimmunotherapy with Tandem Stem-Cell Autografting Has Promising Activity, Minimal Toxicity and Full Feasibility in an Outpatient Setting.. Blood. 108(11). 3047–3047. 9 indexed citations

17.

Ladetto, Marco, Michele Magni, G Pagliano, et al.. (2006). Rituximab Induces Effective Clearance of Minimal Residual Disease in Molecular Relapses of Mantle Cell Lymphoma. Biology of Blood and Marrow Transplantation. 12(12). 1270–1276. 43 indexed citations

18.

Carlo‐Stella, Carmelo, Massimo Di Nicola, Paolo Longoni, et al.. (2004). Mobilization of primitive and committed hematopoietic progenitors in nonhuman primates treated with defibrotide and recombinant human granulocyte colony-stimulating factor. Experimental Hematology. 32(1). 68–75. 6 indexed citations

19.

Carlo‐Stella, Carmelo, Massimo Di Nicola, Raffaella Milani, et al.. (2004). Age- and irradiation-associated loss of bone marrow hematopoietic function in mice is reversed by recombinant human growth hormone. Experimental Hematology. 32(2). 171–178. 36 indexed citations

20.

Nicola, Massimo Di, Carmelo Carlo‐Stella, Jacopo Mariotti, et al.. (2004). High response rate and manageable toxicity with an intensive, short‐term chemotherapy programme for Burkitt's lymphoma in adults. British Journal of Haematology. 126(6). 815–820. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact